Acorda Therapeutics’ Online Multiple Sclerosis Resources To Be Demonstrated in Dallas

Click here to receive MS news via e-mail
Acorda Therapeutics

MS self™ mobile appAt the 2014 Cooperative Meeting of the Consortium of Multiple Sclerosis Centers and the Americas Committee for Treatment and Research in Multiple Sclerosis on May 28-31 in Dallas, Acorda Therapeutics will be demonstrating its award-winning MS self™ mobile app designed for patients with multiple sclerosis. Acorda promotes the saying, “With MS, Knowledge is Power,” and their MS self app is designed to empower individuals living with multiple sclerosis.

MS self app is part of the initiative from Acorda. “We developed and MS self to help people proactively manage the challenges they face living with multiple sclerosis. We are excited to share these digital tools with the healthcare professionals attending the CMSC/ACTRIMS meeting, providing them with additional resources for their patients,” said Adrian Rabinowicz, Acorda’s Senior Vice President, Clinical Development and Medical Affairs, in a news release. The site contains videos, articles, and downloadable information.

The application is an extension of their web-based tools. MS self app allows 24/7 access to tools such as a thoughts journal, Fact Cards, and a documentation of individual progress. It was recently updated on the iTunes store and is free to download for iPhone and iPad.

[adrotate group=”4″]

Acorda TherapeuticsAcorda Therapeutics was founded in 1995. “Our company’s mission is to improve the lives of people with neurological disorders. Research and development of novel medicines is a core component of our mission, as is providing support to people with multiple sclerosis, their care partners and healthcare team,” said Rabinowicz. In addition to their web source, three FDA-approved therapies are in use to help multiple sclerosis patients, and six clinical-stage and one preclinical therapies are in the pipeline for neurological disease.

Tagged , .

Maureen Newman is a science columnist for BioNews Texas. She is currently a PhD student studying biomedical engineering at University of Rochester, working towards a career of research in biomaterials for drug delivery and regenerative medicine. She is an integral part of Dr. Danielle Benoit's laboratory, where she is investigating bone-homing therapeutics for osteoporosis treatment.
Click here to receive MS news via e-mail


Leave a Comment

Your email address will not be published. Required fields are marked *